AstraZeneca Plc - Kewajiban jangka dawa perusahaan AZN

AstraZeneca PLC (AZN) strategy relies on expansion into biopharmaceuticals and oncology through targeted acquisitions. The valuation of the corporation's long-term loans and borrowings visualizes the debt load, where 26.60 determines the current status of the parameter. Modern plants in the US and Europe ensure production stability, while Pascal Soriot's experienced management guarantees the confident development of the rare disease portfolio.

AZN Kewajiban jangka dawa perusahaan astrazeneca.com (04.07.2022 - 28.10.2026)

Rincian metrik keuangan lan pasar AstraZeneca AB (AZN)

- rega lan prakiraan konsensus rega:

Bagan owah-owahan rega astrazeneca.com|AZN - Bagan rega target

- data kapitalisasi pasar:

Biji pasar AstraZeneca|AZN - Nilai Perusahaan

- data kapitalisasi buku:

Nilai Buku saben Saham AstraZeneca|AZN - Aset Bersih Perusahaan|Nilai Pasar marang Nilai Buku astrazeneca.com|AZN - Total Aset Perusahaan

- data utang lan likuiditas:

Rasio Kabeh Utang marang Dana Pribadi AstraZeneca PLC|AZN - Utang jangka dawa marang ekuitas|Kewajiban jangka cendhak marang modal AstraZeneca Corp.|AZN - Utang perusahaan|Rasio utang marang kapitalisasi buku AstraZeneca|AZN - Utang jangka dawa perusahaan|Tanggungan utang jangka cendhak perusahaan AstraZeneca

Analisis kabeh metrik perusahaan:AZN (astrazeneca.com)

Long-term debt measures the total volume of credit obligations with maturities exceeding one year, determining financial stability and the cost of capital. For AstraZeneca PLC (AZN), this resource is critical during logistics chain disruptions and global research failures caused by geopolitics. By analyzing the trajectory of the company's long-term debt, an investor assesses the balance between R&D investments and liquidity risk. A reduction in the debt load confirms a conservative profile and the reliability of the issuer.

Analisis pesaing